Corvus to Present Initial Soquelitinib ALPS Trial Data at Hematology Meeting
The ongoing Phase 2 trial is led by NIAID researchers. The company says data from three patients show positive one-year safety and efficacy results.
Story updates
02:07:46 PM UTC
SquawkNews
In an ongoing Phase 2 ALPS trial, three patients completed one year of soquelitinib treatment at 200 mg twice daily. No grade 3 or 4 adverse events or therapy interruptions occurred; all discontinued background medications and reported improved systemic symptoms.Material DetailsContext by AI Analys…